Posted on

Zylorion Announces Filing of U.S. Provisional Patent For Novel Second-Generation Psilocybin-Based Compound

Zylorion Announces Filing of U.S. Provisional Patent For Novel Second-Generation Psilocybin-Based Compound

CALGARY, AB, July 14, 2022 /CNW/ –  PsiloTec Health Solutions Inc., operating as Zylorion Health, (“Zylorion” or the “Company”), a precision mental health care and psychedelic therapy focused innovator, is pleased to announce the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”).

The provisional patent application covers the composition of matter of Zylorion’s novel psilocybin-based compound, ZYL-314, for the treatment of mental health disorders and other central nervous system conditions and cognitive disorders.

“Our clinical team has been working tirelessly with our research partners on the development of novel second generation and industry leading compounds, and we are extremely excited about this discovery,” commented Dr. Peter Silverstone, Chief Executive Officer. “ZYL-314 is truly unique and achieving this milestone demonstrates Zylorion’s commitment to bringing innovative new therapies to market and creating long-term shareholder value through a strong portfolio of intellectual property assets”.    

The Company continues to gather the necessary data and evidence to support the claims and conversion of the composition of matter provisional patent and anticipates filing an application under the PCT (Patent Cooperation Treaty) within the next twelve months.

About Zylorion

Zylorion is a biotech company engaged in the development and delivery of integrated precision mental health therapies to address psychological and neurological mental health conditions. Zylorion is focused on the research, development and commercialization of psychedelic-based compounds coupled with novel therapeutic treatment programs targeting a continuum of mental health conditions, such as MDD (major depressive disorder), TRD (treatment resistant depression), PTSD (post-traumatic stress disorder), general depression, anxiety disorders, and a number of addictive tendencies. Zylorion aims to leverage leading technologies to support the scalability and accessibility of its integrated therapy programs in its mission to enable those experiencing mental health challenges to thrive. Cautionary Note Regarding Forward-Looking Statements

This news release contains statements that constitute forward-looking information (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

SOURCE Zylorion

For further information: Investor Relations, e: InvestorRelations@zylorion.com ; General Enquiries & Media Relations, e: Info@zylorion.com, www.zylorion.com

Posted on

Filament Health Issued Third Patent by United States Patent and Trademark Office

Filament Health Issued Third Patent by United States Patent and Trademark Office

The patent describes the extraction and standardization of stable doses of psychedelic compounds

Vancouver, British Columbia, July 12, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming psychedelic raw materials into pharmaceutical-grade, standardized drug candidates. 

“The continued growth of Filament’s American patent portfolio is a testament to the strength of our drug development platform,” said Benjamin Lightburn, Chief Executive Officer. “This approval represents the viability of our IP strategy in the US in addition to our success in Canada.”

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. The Company now holds seven patents, four in Canada and three in the United States, including the first-ever patent for the extraction and standardization of natural psilocybin which was issued on August 3, 2021.

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn

FILAMENT HEALTH

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

INVESTOR RELATIONS

ir@filament.health

FORWARD LOOKING STATEMENTS

Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.30

Posted on

Filament Health Announces Sixth Patent Issuance

Filament Health Announces Sixth Patent Issuance

The patent describes the extraction and standardization of stable doses of psychedelic compounds

Vancouver, British Columbia, July 6, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a sixth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.

“The continued growth of our patent portfolio validates Filament’s strong intellectual property strategy and drug development platform,” said Ryan Moss, Chief Science Officer at Filament Health. “Our ability to transform valuable natural substances into IP-protected pharmaceutical-grade drug candidates sets us apart as industry leaders.”

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. On August 3, 2021, Filament was issued the first-ever patent for the extraction and standardization of natural psilocybin. In under a year, the Company has been issued a total of four patents by CIPO and two by the United States Patent and Trademark Office.

“Since Filament’s founding, we have endeavoured to identify the most efficient means to extract naturally sourced fungal APIs,” said Taran Grey, Director of Intellectual Property. “We are proud to add yet another functional patent to our portfolio that describes more of the ways we produce novel drug candidates each and every day.”

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn

FILAMENT HEALTH

Anna Cordon, Director of Communications
778.245.9067
anna@filament.health

INVESTOR RELATIONS

ir@filament.health

FORWARD LOOKING STATEMENTS

Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.306

Posted on

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication

San Diego, California — (June 29, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment of patients with Binge Eating disorder (BED).

The new patent application is part of Tryp’s corporate strategy to expand the clinical utility of psilocybin-assisted therapy in patients with BED who are awaiting transformative medicines. Tryp’s Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial in collaboration with the University of Florida, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. The initial data readout for the first patient dosed in the STOP trial showed potential benefit for patients with BED, further supporting the Company’s commitment to developing psilocybin based therapies for patients with eating disorders. Once issued, the new patent will provide Tryp with an Intellectual Property Protection for BED utilizing its psilocybin-based candidates TRP-8802 and TRP-8803.

“We have elected to pursue indications that are distinct from other industry players, thereby distinguishing our research and development pipeline among our peers,” said Jim Gilligan, Interim CEO and Chief Scientific Officer, Tryp Therapeutics. “TRP-8802, our clinical candidate, has shown promising early data endpoints. The expansion of our patent portfolio enables us to develop a psychedelic treatment in conjunction with psychotherapy for BED patients while also strengthening Tryp’s position as an industry leader with an expanding Intellectual Property Estate.”

Tryp is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. In disorders where efficacy is indicated, Tryp’s lead drug candidate TRP-8803 which is being developed concurrently, will be studied in subsequent trials. TRP-8803 includes a unique formulation and delivery system and is designed to enhance the positive effects of psilocybin and psilocybin-related compounds, while markedly reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal and sublingual.

About Binge Eating Disorder (BED)

  • BED is characterized by recurring episodes of eating large quantities of food and feeling unable to stop.
  • Nearly 30% of people seeking weight loss treatments show signs of BED.
  • Up to 3.5% of females and 2.0% of males will develop BED at some point in their lives – nearly 4 million women and 2 million men in the United States; treatments to date have not been effective.


About Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The Company has begun enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Relations:
Jim Gilligan, Interim CEO
Tryp Therapeutics
jgilligan@tryptherapeutics.com

Media Relations:
Francesca DeMauro
KCSA Strategic Communications
TRYP@KCSA.com

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes

Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders

ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting autoimmune diseases.

Eric Weisblum, CEO of Silo Pharma commented “We are delighted to expand our partnership with UMB.  Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model.  To test the therapeutic effect of the peptides, arthritic Lewis rats (n=4/group) were injected intravenously with one of the peptides or PBS either at the onset or just following the onset of arthritis. The rats were monitored regularly for disease severity and were assigned an “arthritic score.” The results show treatment of arthritic Lewis rats with two of the three phage-encoded peptides (NQR and RGD) suppresses adjuvant arthritis, with RGD producing the most robust effect. Therefore, phage peptides ADK homes to the synovial vasculature of the inflamed joint, while phage peptides NQR and RGD both home to this area of the inflamed joint and have a therapeutic effect in a rat model of arthritis. The global market for auto-immune disease therapeutics is projected to be over $150 billion by 2025. We believe the issued patent portfolio that comes with these assets allows Silo to further advance its value to investors and future partners.”

About Silo Pharma 
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements 
This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact: 
Hayden IR 
Brett Maas 
646-536-7331 
Email: brett@haydenir.com

Posted on

Numinus Applies for International Patent Filing of Psychedelics Production Process

Numinus Applies for International Patent Filing of Psychedelics Production Process

Filing would offer added protection to IP already submitted to USPTO

VANCOUVER, BC, June 22, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process for Psilocybe and other fungi species containing psilocybin and other compounds.

A provisional patent application for the process was submitted to the United States Patent & Trademark Office (USPTO) on June 24, 2021. With this additional filing, international patent protection would extend to all WIPO member states that have signed the Patent Cooperation Treaty (PCT), including Australia, Germany, Netherlands and the United Kingdom, where psychedelic research is currently active.

“The WIPO is an important global forum that provides reassurance to the patent offices of member states. Numinus is confident that the robust evidence supporting the production process will further inform regulators as they consider policy changes to make psychedelic-assisted therapies and products more accessible,” said Sharan Sidhu, VP, Scientific Research, Innovation & Laboratory Operations, Numinus. “We look forward to advancing current research and paving the way for eventual commercialization and mainstream access.”

The purpose of the process is to significantly increase production of therapeutics for use in psychedelic-assisted therapy, while reducing product variability, increasing production efficiency and ultimately reducing commercialization costs. Since the initial filing, data-sets validating the process for additional fungi specifies have been completed, broadening its potential application and scope from psilocybin to other active compounds.

“This application is part of Numinus’ long-term IP strategic focus on scalable and sustainable production that advances research, development and delivery of innovative psychedelic-derived formulations in North America and beyond,” said Payton Nyquvest, Founder and CEO, Numinus.About Numinus

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. 

Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Disclaimer

Neither Numinus Wellness Inc., nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a corporation if that corporation holds a valid permit to do so, Numinus and its subsidiaries operate in a management services function to affiliated professional corporations, who provide health services to patients. Numinus and its subsidiaries do provide health services directly to patients in those jurisdictions where authorized to do so.

Forward-Looking Statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc.

For further information: Investor Contact: Jamie Kokoska, Vice President, Investor Relations & Communications, jamie.kokoska@numinus.com; Media Contact: May Lee, Communications Manager, may.lee@numinus.com

Posted on

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

 
mRNA Diagnostic Index to Measure Drug Treatment Response

Vancouver, British Columbia – June 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its IP with the filing of provisional patent applications to protect data it obtained during its psilocybin preclinical studies and provide protection for the Company’s therapeutic paradigm for treating neuroinflammatory disorders with psilocybin and psilocybin-based tryptamine derivatives.

“The filing of these patent applications represent a major milestone in NOVA’s psilocybin research program,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “The Company is now in a position to reveal the breakthrough preclinical psilocybin results uncovered in its treatment of fragile X syndrome (FXS). Oral repetitive doses of microdose psilocybin showed a more robust improvement in memory than the same doses given by injection. Metabolic changes of psilocybin within the small intestine and perhaps the microbiome may represent a new paradigm in the application of psilocybin to the treatment of autism spectrum disorder (ASD). The data is scheduled to be published in a peer reviewed journal and presented at the upcoming 18th NFXF International Fragile X Conference in July 2022.” The provisional patent applications filed with the U.S. Patent and Trademark Office relates to diagnosis, monitoring and treating neuroinflammatory diseases and conditions with psychoactive tryptamine derivatives.

NOVA’s psilocybin formulation was evaluated in two distinct rat models of autism in the laboratory of Dr. Viviana Trezza, Rome, Italy, and demonstrated psilocybin proof of efficacy and safety. In February 2022, the Company announced it had successfully completed a preclinical study that confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS. The research found that a repeated low dose of NOVA’s proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects, such as recognition memory, in a genetic model of FXS.

Neuroinflammatory conditions – especially those that have the added complexity of disrupted emotional states and behaviours – are still difficult to diagnose accurately and treat effectively. NOVA’s research program is designed to generate clinical biomarker data that characterize aberrant gene expression and cellular communication in neurological disease or injury and provide insights into possible interventions and disease monitoring.

The ability to penetrate the unique genetic language underlying the development of chronic diseases and assess therapeutic responses will assist NOVA in obtaining psychedelic drug approval with the regulatory agencies.

In July 2021, NOVA filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin. In May and November 2021, the Company filed US provisional patent applications describing a diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, FXS and ASD. 

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.
Posted on

Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India

Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India

The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks

VANCOUVER, June 01, 2022 — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company’s proprietary MEAI-based alcohol substitute patent family.

‍”Our innovation continues to gain global recognition, this time by the Indian patent office.” said Dr. Adi Zuloff- Shani, Clearmind’s Chief Executive Officer. “Clearmind is the sole owner of a family of patents concerning a synthetic substance as a replacement for alcohol.

‍“We will address the tremendous global problem of alcohol abuse by developing both approved treatments and food supplements,” she added.

‍Clearmind was previously also granted patents for this application in Europe and has pending applications in the United States and China for this patent family.

‍About Clearmind Medicine Inc.

Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.

‍The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

‍Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWY0” and on the OTC pink under the symbol “CMNDF“.

‍For further information, please contact:

‍Investor Relations,

Email: invest@clearmindmedicine.com

‍Telephone: (604) 260-1566

General Inquiries,

‍Info@Clearmindmedicine.com

‍‍www.Clearmindmedicine.com

‍‍FORWARD-LOOKING STATEMENTS:

‍This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.‍

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful.‍

The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin

  • Patent claims cover methods of administering psilocybin and psilocin to patients having reduced monoamine oxidase A activity
  • New patent expires in 2041
  • Given implications to patient safety, Lennham’s discoveries are likely to cover information in the label of any future psilocybin- or psilocin-based product or structurally related compounds

May 31, 2022 10:03 AM Eastern Daylight Time

CONCORD, Mass.–(BUSINESS WIRE)–Lennham Pharmaceuticals, a start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of psilocybin or psilocin.

“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS”Tweet this

“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS,” said Bradford C. Sippy, Founder of Lennham. “Although glucoronidation is psilocin’s primary metabolic route systemically, metabolism by MAO-A plays a much greater role at the site of action. The use of psilocybin or psilocin in patients having an MAO-A deficiency requires a new approach to administration of those products. Our newly issued patent covers methods of using psilocybin and psilocin in these patient populations, which we believe will be incorporated into the eventual labeling for any psilocybin- or psilocin-based product.”

About Psilocybin
Psilocybin is a well-known, naturally occurring chemical in certain mushrooms that is known to produce hallucinogenic (psychedelic) effects in humans when consumed. It is currently being evaluated as a potential treatment for treatment-resistant depression1 and major depressive disorder, among other diseases and conditions.

About Lennham Pharmaceuticals, Inc.
Lennham is a privately held, life sciences company focused on the creative application of deuterium chemistry to highly utilized and well-characterized compounds. Founded in 2019, Lennham’s unique approach to deuteration has enabled it to rapidly develop a pipeline of product candidates, including deuterium-enriched forms of psilocybin, caffeine, and testosterone.

For more information please visit www.lennham.com or contact info@lennham.com.

References

  1. Carhart-Harris R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411

Contacts

Media:
Corey MacGregor
Chief Business Officer
Lennham Pharmaceuticals
Corey.macgregor@lennham.com
(978) 254-3201

Posted on

Update on Awakn’s ketamine study

Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions

Awakn Life Sciences (AWKN) filed an international patent application for its ketamine treatment for behavioural addictions like gambling, gaming, binge eating, and compulsive sexual behaviour. 

Plus, the company shared a bit more info on the “hugely promising” pilot study mentioned last week.

The treatment was found to reduce symptoms of addiction as well as comorbid conditions like depression and anxiety. Some patients no longer qualified for a diagnosis of addiction after the ketamine therapy.

PDF of article